Prevalence of autoantibodies against Ras‑like GTPases, RalA, in patients with gastric cancer
- Authors:
- Published online on: July 20, 2020 https://doi.org/10.3892/mco.2020.2098
- Article Number: 28
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Ras‑like GTPases, RalA and RalB, are members of the Ras superfamily of small GTPases. RalA expression has been shown to be associated with aggressive clinicopathological characteristics and progression in cancer. RalA protein has been shown to be involved in immune reactions in some patients with cancer; however, the clinicopathological significance of serum RalA antibody in patients with gastric cancer has not been investigated. Serum samples of 291 patients with gastric cancer and 73 healthy controls were analyzed for serum RalA antibody using enzyme‑linked immunosorbent assay. A cut‑off optical density value was fixed at 0.255 (mean of control + 2 standard deviations). The clinicopathological and prognostic significance of s‑RalA‑Abs was evaluated. The positivity rate for serum RalA antibody (s‑RalA‑Abs) was 15%. The presence of serum RalA antibody was higher in younger patients compared with elderly patients, however this tendency was not statistically significant. s‑RalA‑Abs was not associated with tumor stage. Since s‑RalA‑Abs was independent of CEA (carcinoembryonic antigen) and carbohydrate antigen 19‑9 (CA19‑9), the combination of s‑RalA‑Abs with CEA and CA19‑9 significantly increased the detection rate of gastric cancer at each tumor stage. Patients who were tested positive for s‑RalA‑Abs showed poor long‑term survival; however, this association was not statistically significant by multivariate analysis. In conclusion, s‑RalA‑Abs may be a candidate serum marker for gastric cancer, when used in combination with CEA and/or CA19‑9. Additionally, the presence of s‑RalA‑Abs, in combination with CEA and/or CA19‑9, was associated with poor survival in patients with gastric cancer.
